Valeo Pharma (TSX:VPH) Debt-to-Equity : -1.40 (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma Debt-to-Equity?

Valeo Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$30.74 Mil. Valeo Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$35.01 Mil. Valeo Pharma's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$-47.01 Mil. Valeo Pharma's debt to equity for the quarter that ended in Jan. 2024 was -1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Valeo Pharma's Debt-to-Equity or its related term are showing as below:

TSX:VPH' s Debt-to-Equity Range Over the Past 10 Years
Min: -45.5 Med: -1.71 Max: 37.63
Current: -1.4

During the past 7 years, the highest Debt-to-Equity Ratio of Valeo Pharma was 37.63. The lowest was -45.50. And the median was -1.71.

TSX:VPH's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs TSX:VPH: -1.40

Valeo Pharma Debt-to-Equity Historical Data

The historical data trend for Valeo Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma Debt-to-Equity Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

-45.50

1.06

3.74

-3.44

-1.62

Valeo Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															-2.62	-2.15	-1.79	-1.62	-1.40

Competitive Comparison of Valeo Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valeo Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's Debt-to-Equity falls into.

Valeo Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Valeo Pharma's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.67	+	60.499)	/	-40.337
	=	-1.62

Valeo Pharma's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(30.738	+	35.008)	/	-47.013
	=	-1.40

Valeo Pharma (TSX:VPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Valeo Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Valeo Pharma (TSX:VPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VPHIF:USA

Address

16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website

https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

Executives

Luc Mainville

Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines